{"article":{"annotation":{"article_id":"ose-combi-ted-phase2-reports-one-year-survival-results-2026","available_at":"2026-10-19T09:47:57.550547Z","geography_revision":"ef6ee0010dda5fe7b240fd514749b43e214c57da73222d2e40ec83b276dd0977","id":"79751c016e7544a6a49508a3bbdb2df47ef7cd8d346515859a56073babb26961","input_sha256":"1d8f54161408e852cc01876db373015cf251b825050289570a2c3f9a956156ae","limitations":["Rule-derived subjects are candidates, not verified editorial labels or calibrated model probabilities.","Coverage is distinct from event location. Unknown country/city/coordinates remain absent; no automatic geocoding.","Article geometries keep their stated precision and methodology; reproducing them is not independent coordinate verification."],"method":"controlled-rules-v1","places":[{"admin1":null,"city":null,"coordinate_note":null,"coordinate_reference_system":"OGC:CRS84","coordinate_source":null,"country":"FR","evidence":[{"field":"country","language":"en","note":"Explicit preserved editorial country/region; no city or national centroid inferred","source_urls":["https://www.ose-immuno.com/wp-content/uploads/2026/10/EN_2601019_OSE-Immunotherapeutics-Combi-TED-2026-ESMO-Abstract-vdef.pdf"]}],"geometry":null,"id":"iso3166-1:FR","kind":"country-or-area","labels":{"ar":"فرنسا","en":"France","es":"Francia","fr":"France"},"match_status":"candidate","precision":"regional","role":"coverage","uncertainty_m":null}],"rules_sha256":"fb5ad3c27c91cb840f7a0a05f7f64a5cb26ad0374409ff9457f277c7092e22b4","schema_version":1,"subjects":[{"concept_id":"medtop:20000447","confidence":null,"confidence_method":null,"evidence":[{"field":"en.title+en.summary","language":"en","note":"Subject suggested from the title or summary: cancer","source_urls":["https://www.ose-immuno.com/wp-content/uploads/2026/10/EN_2601019_OSE-Immunotherapeutics-Combi-TED-2026-ESMO-Abstract-vdef.pdf"]}],"method":"controlled-rules-v1","rule_id":"cancer","status":"candidate"}],"taxonomy_revision":"1f2db31d811fca07e99b16d402c10e2cc2965c9df1c7b41d9be348b40a24e7fb","taxonomy_version":"IPTC Media Topics 2026-Q2"},"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=fr","category":"health","content":{"key_points":[],"paragraphs":["D’après le communiqué du 19 octobre, l’essai international, ouvert et randomisé Combi-TED, parrainé par FoRT, évaluait un traitement de deuxième ligne du cancer du poumon non à petites cellules métastatique. Il a inclus 106 patients HLA-A2 positifs dans 19 centres en France, en Italie et en Espagne. Tedopi était associé soit au docétaxel, soit au nivolumab ; ces associations étaient comparées au docétaxel seul.","La survie globale à un an était le critère principal. OSE a rapporté des taux de 47 % pour Tedopi associé au docétaxel, de 46 % pour Tedopi associé au nivolumab et de 29 % pour le docétaxel seul. Le communiqué préliminaire donne l’effectif total, sans préciser les effectifs par groupe ni les intervalles de confiance de ces taux. Les résultats détaillés doivent être présentés le 25 octobre au congrès de l’ESMO à Madrid."],"sections":[]},"corrections":[],"country":"FR","data":{"blocks":[{"columns":[{"key":"arm","label":{"ar":"ذراع العلاج","de":"Behandlungsarm","en":"Treatment arm","es":"Grupo de tratamiento","fr":"Bras de traitement","pt":"Braço de tratamento","tr":"Tedavi kolu"},"language":"en","type":"text"},{"key":"rate","label":{"ar":"البقاء الإجمالي بعد عام","de":"Gesamtüberleben nach einem Jahr","en":"One-year overall survival","es":"Supervivencia global al año","fr":"Survie globale à un an","pt":"Sobrevivência global ao fim de um ano","tr":"Bir yıllık genel sağkalım"},"type":"number","unit":"percent"}],"description":{"ar":"النتائج التي أوردتها OSE عن دراسة Combi-TED من المرحلة الثانية في بيانها الصادر في 19 أكتوبر 2026.","de":"Im OSE-Kommuniqué vom 19. Oktober 2026 berichtete Ergebnisse der Combi-TED-Phase-2-Studie.","en":"Results reported for the Combi-TED Phase 2 study in OSE’s press release dated 19 October 2026.","es":"Resultados comunicados del ensayo de fase 2 Combi-TED en el comunicado de OSE del 19 de octubre de 2026.","fr":"Résultats rapportés pour l’essai de phase 2 Combi-TED dans le communiqué d’OSE du 19 octobre 2026.","pt":"Resultados comunicados para o ensaio de fase 2 Combi-TED no comunicado da OSE de 19 de outubro de 2026.","tr":"OSE’nin 19 Ekim 2026 tarihli basın açıklamasında Combi-TED Faz 2 çalışması için bildirdiği sonuçlar."},"id":"combi-ted-one-year-survival","methodology":{"ar":"نسب البقاء الإجمالي بعد عام التي أعلنتها الشركة للتجربة العشوائية المفتوحة من المرحلة الثانية. لم تُحسب المعدلات أو تُعدّل. يذكر البيان 106 مشاركين إجمالاً دون أعداد كل مجموعة أو فواصل الثقة لهذه المعدلات.","de":"Vom Unternehmen berichtete Ein-Jahres-Gesamtüberlebensraten der offenen randomisierten Phase-2-Studie. Es wurden keine Raten berechnet oder angepasst. Die Mitteilung nennt insgesamt 106 Patienten, ohne Gruppengrößen oder Konfidenzintervalle für diese Raten.","en":"Company-reported one-year overall-survival percentages for the open-label randomized Phase 2 trial. No rates were calculated or adjusted. The release specifies 106 patients overall, without individual arm sizes or confidence intervals for these rates.","es":"Porcentajes de supervivencia global al año comunicados por la empresa para el ensayo abierto y aleatorizado de fase 2. No se calcularon ni ajustaron tasas. El comunicado indica un total de 106 pacientes, sin tamaños por grupo ni intervalos de confianza de estas tasas.","fr":"Pourcentages de survie globale à un an rapportés par la société pour l’essai ouvert randomisé de phase 2. Aucun taux n’a été calculé ou ajusté. Le communiqué précise un total de 106 patients, sans effectifs par groupe ni intervalles de confiance de ces taux.","pt":"Percentagens de sobrevivência global a um ano comunicadas pela empresa para o ensaio aberto e aleatorizado de fase 2. Não foram calculadas nem ajustadas taxas. O comunicado indica 106 participantes no total, sem efetivos por grupo ou intervalos de confiança destas taxas.","tr":"Açık etiketli, randomize Faz 2 çalışması için şirketin bildirdiği bir yıllık genel sağkalım yüzdeleridir. Oranlar hesaplanmadı veya düzeltilmedi. Açıklama toplam 106 hastayı belirtir, ayrı kol büyüklüklerini ve bu oranların güven aralıklarını vermez."},"rowTranslations":[{"arm":{"ar":"تيدوبي + دوسيتاكسيل","de":"Tedopi + Docetaxel","en":"Tedopi + docetaxel","es":"Tedopi + docetaxel","fr":"Tedopi + docétaxel","pt":"Tedopi + docetaxel","tr":"Tedopi + docetaksel"}},{"arm":{"ar":"تيدوبي + نيفولوماب","de":"Tedopi + Nivolumab","en":"Tedopi + nivolumab","es":"Tedopi + nivolumab","fr":"Tedopi + nivolumab","pt":"Tedopi + nivolumab","tr":"Tedopi + nivolumab"}},{"arm":{"ar":"دوسيتاكسيل وحده","de":"Docetaxel allein","en":"Docetaxel alone","es":"Docetaxel solo","fr":"Docétaxel seul","pt":"Docetaxel isolado","tr":"Yalnız docetaksel"}}],"rows":[{"arm":"Tedopi + docetaxel","rate":47},{"arm":"Tedopi + nivolumab","rate":46},{"arm":"Docetaxel alone","rate":29}],"sourceUrls":["https://www.ose-immuno.com/wp-content/uploads/2026/10/EN_2601019_OSE-Immunotherapeutics-Combi-TED-2026-ESMO-Abstract-vdef.pdf"],"title":{"ar":"البقاء الإجمالي بعد عام في تجربة Combi-TED","de":"Gesamtüberleben nach einem Jahr in Combi-TED","en":"One-year overall survival in Combi-TED","es":"Supervivencia global al año en Combi-TED","fr":"Survie globale à un an dans Combi-TED","pt":"Sobrevivência global ao fim de um ano no Combi-TED","tr":"Combi-TED çalışmasında bir yıllık genel sağkalım"},"type":"table","updatedAt":"2026-10-19T08:16:12Z"}],"version":1},"data_downloads":[{"formats":{"csv":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026/data/combi-ted-one-year-survival?lang=fr&format=csv","json":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026/data/combi-ted-one-year-survival?lang=fr&format=json"},"id":"combi-ted-one-year-survival"}],"data_types":["table"],"editorial_illustration":{"alt":"Illustration conceptuelle de la santé publique, de la recherche et des données connectées.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"fr","scope":"topic","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"event_id":"event-b2a13bbd-82b6-5259-9a42-3a17384910b1","event_period":"2026-10-19","event_period_basis":"event-or-reference-period","id":"ose-combi-ted-phase2-reports-one-year-survival-results-2026","image":null,"importance":0.6,"language":"fr","modified_at":"2026-10-19T09:46:57+00:00","publication_basis":"publication-record","published_at":"2026-10-19T09:46:57+00:00","reading_minutes":1,"region":"world","relations":[],"section_illustration":{"alt":"Illustration conceptuelle de la santé publique, de la recherche et des données connectées.","asset_id":"newsverum-v1-health","avif_variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.avif","width":480},{"height":480,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-720.avif","width":720},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.avif","width":960},{"height":800,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1200.avif","width":1200},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.avif","width":1536}],"credit":"Newsverum","documentary":false,"height":1024,"kind":"symbolic-editorial-illustration","language":"fr","scope":"section","url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","variants":[{"height":320,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-480.webp","width":480},{"height":640,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-960.webp","width":960},{"height":1024,"url":"https://newsverum.com/assets/newsverum/illustrations/v1/health-1536.webp","width":1536}],"width":1536},"slug":"ose-combi-ted-phase2-reports-one-year-survival-results-2026","sources":[{"checkedAt":"2026-10-19","name":"OSE Immunotherapeutics","publishedAt":"2026-10-19","url":"https://www.ose-immuno.com/wp-content/uploads/2026/10/EN_2601019_OSE-Immunotherapeutics-Combi-TED-2026-ESMO-Abstract-vdef.pdf"}],"summary":"La biotech française OSE Immunotherapeutics a publié le 19 octobre les résultats de l’essai de phase 2 Combi-TED. Selon la société, les taux de survie globale à un an étaient plus élevés dans les deux groupes associant Tedopi que dans le groupe recevant uniquement du docétaxel.","text":"La biotech française OSE Immunotherapeutics a publié le 19 octobre les résultats de l’essai de phase 2 Combi-TED. Selon la société, les taux de survie globale à un an étaient plus élevés dans les deux groupes associant Tedopi que dans le groupe recevant uniquement du docétaxel.\n\nD’après le communiqué du 19 octobre, l’essai international, ouvert et randomisé Combi-TED, parrainé par FoRT, évaluait un traitement de deuxième ligne du cancer du poumon non à petites cellules métastatique. Il a inclus 106 patients HLA-A2 positifs dans 19 centres en France, en Italie et en Espagne. Tedopi était associé soit au docétaxel, soit au nivolumab ; ces associations étaient comparées au docétaxel seul.\n\nLa survie globale à un an était le critère principal. OSE a rapporté des taux de 47 % pour Tedopi associé au docétaxel, de 46 % pour Tedopi associé au nivolumab et de 29 % pour le docétaxel seul. Le communiqué préliminaire donne l’effectif total, sans préciser les effectifs par groupe ni les intervalles de confiance de ces taux. Les résultats détaillés doivent être présentés le 25 octobre au congrès de l’ESMO à Madrid.","title":"OSE Immunotherapeutics publie les résultats de survie à un an de l’essai Combi-TED","topics":[],"translations":[{"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=tr","language":"tr","url":"https://newsverum.com/tr/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"},{"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=en","language":"en","url":"https://newsverum.com/en/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"},{"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=ar","language":"ar","url":"https://newsverum.com/ar/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"},{"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=fr","language":"fr","url":"https://newsverum.com/fr/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"},{"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=es","language":"es","url":"https://newsverum.com/es/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"},{"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=de","language":"de","url":"https://newsverum.com/de/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"},{"api_url":"https://newsverum.com/api/v1/articles/ose-combi-ted-phase2-reports-one-year-survival-results-2026?lang=pt","language":"pt","url":"https://newsverum.com/pt/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"}],"url":"https://newsverum.com/fr/news/ose-combi-ted-phase2-reports-one-year-survival-results-2026"},"version":"1"}